Kennedy Capital Management, Inc. Cytokinetics Inc Transaction History
Kennedy Capital Management, Inc.
- $4.27 Billion
- Q3 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 5,251 shares of CYTK stock, worth $287,229. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,251
Previous 4,496
16.79%
Holding current value
$287,229
Previous $243,000
13.99%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
407Shares Held
125MCall Options Held
4.52MPut Options Held
2.28M-
Black Rock Inc. New York, NY14.7MShares$803 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$643 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$530 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$425 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$353 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.15B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...